Crystal Lloyd, APRN
Family · Osage Beach, MONPI 1487495206
Payments from drug & device makers
Across 111 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$370
- Novartis$241
- Pfizer$162
- UCB, Inc.$158
- Neurelis, Inc.$137
- Biogen$102
- plus $783 from 19 others
What the payments were for
- Food & beverage$1,954100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 20 | $370 |
| Novartis | 13 | $241 |
| Pfizer | 19 | $162 |
| UCB, Inc. | 11 | $158 |
| Neurelis, Inc. | 5 | $137 |
| Biogen | 5 | $102 |
| EMD Serono, Inc. | 4 | $84 |
| Eisai Inc. | 4 | $80 |
| ANI Pharmaceuticals, Inc. | 4 | $80 |
| Otsuka America Pharmaceutical, Inc. | 3 | $69 |
| Lundbeck LLC | 3 | $50 |
| Mallinckrodt Hospital Products Inc. | 2 | $45 |
| SK Life Science, Inc. | 2 | $42 |
| Argenx US, Inc. | 2 | $42 |
| TG Therapeutics, Inc. | 2 | $42 |
| Tanabe Pharma America, Inc. | 2 | $40 |
| Genentech USA, Inc. | 2 | $35 |
| Sanofi | 1 | $26 |
| Banner Life Sciences, LLC | 1 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| Chiesi USA, Inc. | 1 | $23 |
| Acadia Pharmaceuticals Inc | 1 | $21 |
| Lilly USA, LLC | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Averitas Pharma Inc. | 1 | $18 |
How this compares
$1,954 in reported general payments places this provider in the 80th percentile of 3,812 family providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Duloxetine Hcl | 34 | $619 |
| Propranolol Hcl | 32 | $423 |
| Levetiracetam | 14 | $293 |
| Memantine Hcl | 20 | $283 |
| Gabapentin | 12 | $265 |
| Donepezil Hcl | 41 | $193 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 16 | $158 |
| Amitriptyline Hcl | 19 | $139 |
| Topiramate | 17 | $109 |
| Trazodone Hcl | 11 | $30 |
| Citalopram HbrCitalopram Hydrobromide | 12 | $8 |
Paid to pharmacies, not to this prescriber.
Other family in Osage Beach
- Connie SpencerSaint Joseph$320K
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Laura HedigerSpringfield$71K
- Rebecca SeabaughSaint Louis$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.